The BioLingus technology has been developed over many years. The focus is to allow "biological drugs", which are almost all administered by injection, to be administered in an oral (sublingual) tablet.
The technology is mature and can be applied to peptides, proteins and vaccines.
Proof of concept is available for each of these types of molecules. Our initial key therapeutic focus for internal development is diabetes (patients take injections daily over their lifetime) and inflammatory diseases.